Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

被引：23

作者：

Young, Kate ^{[1
]}

Smyth, Elizabeth ^{[1
]}

Chau, Ian ^{[1
]}

机构：

[1] Royal Marsden Hosp, Gastrointestinal Oncol Unit, Sutton SM2 5PT, Surrey, England

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2015年 / 8卷 / 06期

关键词：

angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2; RANDOMIZED PHASE-III; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; OPEN-LABEL; GROWTH; COMBINATION; PLUS; VEGF;

D O I：

10.1177/1756283X15592586

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

引用

页码：373 / 383

页数：11

共 50 条

[41] Survival Outcomes for Peri-operative chemotherapy for Oesophageal and Gastro-Oesophageal Junction adenocarcinoma
Goody, R.
McManus, D.
Kennedy, R.
Eatock, M.
Turkington, R. C.
BRITISH JOURNAL OF SURGERY, 2016, 103 : 144 - 144
[42] Adenocarcinoma of the gastro-oesophageal junction after sleeve gastrectomy: a case report
Sohn, Sangsu
Fischer, Jesse
Booth, Michael
ANZ JOURNAL OF SURGERY, 2017, 87 (10) : E163 - E164
[43] Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
Li, Minmin
Chan, David
Li, Bob T.
Pavlakis, Nick
Kneebone, Andrew
Bailey, Dale
Clarke, Stephen
OXFORD MEDICAL CASE REPORTS, 2014, (06): : 105 - 106
[44] Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer
Wagner, Anna D.
Lordick, Florian
Grabsch, Heike, I
Terashima, Masanori
Terada, Mitsumi
Yoshikawa, Takaki
Boku, Narikazu
Kataoka, Kozo
Smyth, Elizabeth C.
Mauer, Murielle
Haustermans, Karin
Moehler, Markus H.
EUROPEAN JOURNAL OF CANCER, 2020, 124 : 67 - 76
[45] Preoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma
Ilson, David
LANCET ONCOLOGY, 2023, 24 (06): : 593 - 595
[46] Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Bang, Yung-Jue
Golan, Talia
Dahan, Laetitia
Fu, Siqing
Moreno, Victor
Park, Keunchil
Geva, Ravit
De Braud, Filippo
Wainberg, Zev A.
Reck, Martin
Goff, Laura
Laing, Naomi
Mi, Gu
Oliveira, Joana M.
Wasserstrom, Heather
Lin, Chia-Chi
EUROPEAN JOURNAL OF CANCER, 2020, 137 : 272 - 284
[47] European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions
Pavlakis, Nick
Tincknell, Gary
Lim, Lisi Elizabeth
Muro, Kei
Obermannova, Radka
Lorenzen, Sylvie
Chua, Yu Jo
Jackson, Chris
Karapetis, Christos Stelios
Price, Timothy
Chantrill, Lorraine
Segelov, Eva
Lordick, Florian
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[48] Benign diseases of the gastro-oesophageal junction
Nawacki, Lukasz G.
Gluszek, Stanislaw
Kuder, Tadeusz
MEDICAL STUDIES-STUDIA MEDYCZNE, 2016, 32 (04) : 248 - 254
[49] GASTRO-OESOPHAGEAL JUNCTION IN DUODENAL ULCER
EARLAM, RJ
BRITISH JOURNAL OF SURGERY, 1971, 58 (04) : 296 - &
[50] Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
Okines, Alicia F. C.
Cunningham, David
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (05): : 301 - 318

← 1 2 3 4 5 →